Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches

Advanced Drug Delivery Reviews

Volumn 105, Issue , 2016, Pages 3-19

  Khodakov, Dmitriy ^a   Wang, Chunyan ^a   Zhang, David Yu ^a,b  

^a Rice University   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

Hybridization; Molecular diagnostics; Next generation sequencing; Nucleic acid tests; PCR

Indexed keywords

BIOMOLECULES; DIAGNOSIS; NUCLEIC ACIDS;

COMMERCIAL ASSAYS; HYBRIDIZATION; IN-VITRO DIAGNOSTIC; MOLECULAR DIAGNOSTICS; MOLECULAR MECHANISM; NEXT-GENERATION SEQUENCING; NUCLEIC ACID ANALYSIS; RELIABLE DETECTION;

POLYMERASE CHAIN REACTION;

BIOLOGICAL MARKER; DNA; NUCLEIC ACID; PEPTIDE NUCLEIC ACID; RNA; UNCLASSIFIED DRUG; XENO NUCLEIC ACID;

AMPLIFICATION REFRACTORY MUTATION SYSTEM; BLOCKER POLYMERASE CHAIN REACTION; CO AMPLIFICATION AT LOWERED DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; DIGITAL POLYMERASE CHAIN REACTION; DNA BARCODING; DNA SEQUENCE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYBRIDIZATION; IN SITU HYBRIDIZATION; IN VITRO DIAGNOSTICS; IN VITRO STUDY; LABORATORY DEVELOPED TEST; LABORATORY TEST; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSTICS; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYNTHETIC BIOLOGY; GENETICS; MOLECULAR DIAGNOSIS; SEQUENCE ANALYSIS;

HUMANS; HYBRIDIZATION, GENETIC; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

EID: 84969917145     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.005     Document Type: Review

References (157)

1. [1] Sachidanandam, R., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409 (2001), 928–933.
2. [2] Tuzun, E., et al. Fine-scale structural variation of the human genome. Nat. Genet. 37 (2005), 727–732.
3. [3] Verkerk, a J., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65 (1991), 905–914.
4. [4] Kerem, B., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989), 1073–1080.
5. [5] Misale, S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
6. [6] Peifer, M., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44 (2012), 1104–1110.
7. [7] Greenman, C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007), 153–158.
8. [8] Drenkard, E., Ausubel, F.M., Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416 (2002), 740–743.
9. [9] Doublet, B., et al. Variant salmonella genomic island 1-L antibiotic resistance gene cluster in Salmonella enterica Serovar Albany. Emerg. Infect. Dis. 9 (2003), 585–591.
10. [10] Emmadi, Rajyasree, et al. Molecular methods and platforms for infectious diseases testing. J. Mol. Diagn. 13 (2011), 583–604.
11. [11] Zhang, Z., Chan, D.W., The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomark. Prev. 19 (2010), 2995–2999.
12. [12] Marchetti, S., Schellens, J.H.M., The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer 97 (2007), 577–581.
13. [13] FDA-approved next-generation sequencing system could expand clinical genomic testing: experts predict MiSeqDx platform will make genetic testing more affordable for smaller labs. AM. J. Med. Genet. A 164, X-XI.
14. [14] Summary of CAP's Legislative Proposal for the Regulatory Framework of Laboratory-Developed Tests (LDTs). 2015.
15. [15] Proposal for Modernization of CLIA Regulations for Laboratory Developed Testing Procedures (LDPs). 2015.
16. [16] Zhao, Y., Chen, F., Li, Q., Wang, L., Fan, C., Isothermal amplification of nucleic acids. Chem. Rev. 115:22 (2015), 12491–12545.
17. [17] Kristensen, L.S., Hansen, L.L., PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin. Chem. 55 (2009), 1471–1483.
18. [18] Newton, C.R., Graham, a, Heptinstall, L.E., Powell, S.J., Summers, C., Kalsheker, N., Smith, J.C., Markham, a F., Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17 (1989), 2503–2516.
19. [19] Bai, R.-K., Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. Clin. Chem. 50 (2004), 996–1001.
20. [20] Bergallo, M., et al. Evaluation of IFN-γ polymorphism + 874 T/a in patients with recurrent tonsillitis by PCR real time mismatch amplification mutation assay (MAMA real time PCR). Cytokine 71 (2015), 278–282.
21. [21] Angulo, Barbara, et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One, 7, 2012, e43842.
22. [22] Gonzalez de, Castro D., et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br. J. Cancer 107 (2012), 345–351.
23. [23] Marchant, J., Mange, A., Larrieux, M., Costes, V., Solassol, J., Comparative evaluation of the new FDA approved THxIDTM-BRAF test with high resolution melting and sanger sequencing. BMC Cancer, 14, 2014, 519.
24. [24] McKinzie, P.B., Parsons, B.L., Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat. Res. 517 (2002), 209–220.
25. [25] Tan, A.Y.C., Westerman, D. a, Dobrovic, A., A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am. J. Clin. Pathol. 127 (2007), 977–981.
26. [26] Didelot, A., et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp. Mol. Pathol. 92 (2012), 275–280.
27. [27] Life Technologies. Accurate and Sensitive Somatic Mutation Detection Powered by castPCR Technology, 2014.
28. [28] Sherrill, C.B., et al. Nucleic acid analysis using an expanded genetic alphabet to quench fluorescence. J. Am. Chem. Soc. 126 (2004), 4550–4556.
29. [29] Reddington, K., Tuite, N., Minogue, E., Barry, T., A current overview of commercially available nucleic acid diagnostics approaches to detect and identify human gastroenteritis pathogens. Biomol. Detect. Quantif. 1 (2014), 3–7.
30. [30] http://www.swiftbiosci.com/technology/myt-primers.
31. [31] Higgins, Rachel R., Beniprashad, Melissa, Cardona, Mark, Masney, Steven, Low, Donald E., Gubbay, Jonathan B., Evaluation and verification of the Seeplex diarrhea-V ACE assay for simultaneous detection of adenovirus, rotavirus, and norovirus genogroups I and II in clinical stool specimens. J. Clin. Microbiol. 49 (2011), 3154–3162.
32. [32] Orum, H., Nielsen, P.E., Egholm, M., Berg, R.H., Buchardt, O., Stanley, C., Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 21 (1993), 5332–5336.
33. [33] Nagai, Y., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65 (2005), 7276–7282.
34. [34] Diacarta. QClamp KRAS Codon Specific Mutation Detection Kit (Exon 2, 3, 4) Instruction Manual, 2013.
35. [35] Alexiadis, assilios, Watanaskul, Tim, Kosco, Karena, Arnold, Lyle, Abstract: the CEE-selector assay: a tool for the identification of rare allele variants. Cancer Res., 72, 2012, 3198.
36. [36] Li, J., Wang, L., Mamon, H., Kulke, M.H., Berbeco, R., Makrigiorgos, G.M., Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat. Med. 14 (2008), 579–584.
37. [37] Milbury, C.A., Li, J., Liu, P.F., Makrigiorgos, G.M., Cold-PCR: improving the sensitivity of molecular diagnostics assays. Expert. Rev. Mol. Diagn. 11 (2011), 159–169.
38. [38] Santis, G., et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One, 6, 2011, e25191.
39. [39] Milbury, C.A., Li, J., Makrigiorgos, G.M., Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res., 39, 2011, e2-e2.
40. [40] Dobosy, J.R., et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers. BMC Biotechnol., 11, 2011, 80.
41. [41] Mackay, I.M., Arden, K.E., Nitsche, A., Real-time PCR in virology. Nucleic Acids Res. 30 (2002), 1292–1305.
42. [42] Molenkamp, R., van der Ham, A., Schinkel, J., Beld, M., Simultaneous detection of five different DNA targets by real-time Taqman PCR using the Roche LightCycler480: application in viral molecular diagnostics. J. Virol. Methods 141 (2007), 205–211.
43. [43] Tyagi, S., Marras, S.A.E., Kramer, F.R., Wavelength-shifting molecular beacons. Nat. Biotechnol. 18 (2000), 1191–1196.
44. [44] Loeffelholz, M.J., Pong, D.L., Pyles, R.B., Xiong, Y., Miller, a.L., Bufton, K.K., Chonmaitree, T., Comparison of the filmarray respiratory panel and prodesse real-time PCR assays for detection of respiratory pathogens. J. Clin. Microbiol. 49 (2011), 4083–4088.
45. [45] Vogelstein, B., Kinzler, K.W., Digital PCR. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 9236–9241.
46. [46] Ottesen, E., Hong, J.W., Quake, Stephen R., Leadbetter, Jared R., Microfluidic digital PCR enables multigene analysis of individual environmental bacteria. Science 314 (2006), 1464–1467.
47. [47] Taly, Valerie, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59 (2013), 1722–1731.
48. [48] Wicker, N., Carles, A., Mills, I.G., Wolf, M., Veerakumarasivam, A., Edgren, H., Boileau, F., Wasylyk, B., Schalken, J.A., Neal, D.E., Kallioniemi, O., Poch, O., A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics, 8, 2007, 84.
49. [49] Schena, M., Shalon, D., Davis, R.W., Brown, P.O., Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995), 467–470.
50. [50] Perou, C.M., et al. Molecular portraits of human breast tumors. Nature 406 (2000), 747–752.
51. [51] Yuen, T., Wurmbach, E., Pfeffer, R.L., Ebersole, B.J., Sealfon, S.C., Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res., 30, 2002, e48.
52. [52] Pemov, a, Modi, H., Chandler, D.P., Bavykin, S., DNA analysis with multiplex microarray-enhanced PCR. Nucleic Acids Res., 33, 2005, e11.
53. [53] Baughn, L.B., et al. Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet. 208 (2015), 1–18.
54. [54] Eklund, Aron C., Szallasi, Zoltan, Correction of technical bias in clinical microarray data improves concordance with known biological information. Genome Biol., 9, 2008, R26.
55. [55] Salazar, R., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 29 (2011), 17–24.
56. [56] Wittner, BenS, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res. 14 (2008), 2988–2993.
57. [57] Lee, Christine C., McMillin, Gwendolyn A., Babic, Nikolina, Melis, Roberta, Yeo, Kiang-Teck J., Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics InfinitiTM and Luminex CYP2C19 panels. Clin. Chim. Acta 412 (2011), 1133–1137.
58. [58] Pfundt, R., et al. Clinical performance of the CytoScan Dx assay in diagnosing developmental delay/intellectual disability. Genet. Med. 17 (2015), 1–6.
59. [59] Pabbaraju, Kanti, Wong, Sallene, Tokaryk, Kara L., Fonseca, Kevin, Drews, Steven J., Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J. Clin. Microbiol. 49 (2011), 1738–1744.
60. [60] Geiss, G.K., et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26 (2008), 317–325.
61. [61] Chapin, Stephen C., Appleyard, David C., Pregibon, Daniel C., Doyle, Patrick S., Rapid microRNA profiling on encoded gel microparticles. Angew. Chem. 123 (2011), 2337–2341.
62. [62] Wyman, S.K., et al. Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res. 21 (2011), 1450–1461.
63. [63] Shalek, A.K., et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 498 (2013), 236–240.
64. [64] Thisse, C., Thisse, B., High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat. Protoc. 3 (2008), 59–69.
65. [65] Gerdes, M.J., Sevinsky, C.J., Sood, A., Adak, S., Bello, M.O., Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 11982–11987.
66. [66] Ross, Jeffrey S., et al. The HER-2 receptor and breast cancer: ten years of targeted anti HER-2 therapy and personalized medicine. Oncologist 14 (2009), 320–368.
67. [67] Tanner, Minna, et al. Chromogenic in situ hybridization — a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 157 (5), 2000, 1467–1472.
68. [68] Koh, Y.W., Lee, H.J., Lee, J.W., Kang, J., Gong, G., Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod. Pathol. 24 (2011), 794–800.
69. [69] Zhu, C.-Q., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26 (2008), 4268–4275.
70. [70] Parilla Castellar, E.R., et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124 (2014), 1473–1480.
71. [71] Grabinski, Tessa M., Kneynsberg, Andrew, Manfredsson, Fredric P., Kanaan, Nicholas M., A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures. PLoS One, 10, 2015, e0120120.
72. [72] Soleymani, L., Fang, Z., Sargent, E.H., Kelley, S.O., Programming the detection limits of biosensors through controlled nanostructuring. Nat. Nanotechnol. 4 (2009), 844–848.
73. [73] Fang, Z., Soleymani, L., Pampalakis, G., Yoshimoto, M., Squire, J.A., Sargent, E.H., Kelley, S.O., Direct profiling of cancer biomarkers in tumor tissue using a multiplexed nanostructured microelectrode integrated circuit. ACS Nano 3 (2009), 3207–3213.
74. [74] Lee, H., Yoon, T.-J., Figueiredo, J.-L., Swirski, F.K., Weissleder, R., Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 12459–12464.
75. [75] Lee, H., Yoon, T.-J., Weissleder, R., Ultrasensitive detection of bacteria using core–shell nanoparticles and an NMR-filter system. Angew. Chem. Int. Ed. 48 (2009), 5657–5660.
76. [76] Samuel, L.P., Tibbetts, R.J., Agotesku, A., Fey, M., Hensley, R., Meier, F.A., Evaluation of a microarray-based assay for rapid identification of gram-positive organisms and resistance markers in positive blood cultures. J. Clin. Microbiol. 51 (2013), 1188–1192.
77. [77] Giachetti, C., et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J. Clin. Microbiol. 40 (2002), 2408–2419.
78. [78] Van Dijk, E.L., Auger, H., Jaszczyszyn, Y., Thermes, C., Ten years of next-generation sequencing technology. Trends Genet. 30 (2014), 418–426.
79. [79] Eisenstein, M., The battle for sequencing supremacy. Nat. Biotechnol. 30 (2012), 1023–1026.
80. [80] Squillace, R., Frampton, G., Stephens, P.J., Ross, J.S., Miller, V.A., Comparing two assays for clinical genomic profiling: the devil is in the data. Onco. Targets. Ther. 8 (2015), 2237–2242.
81. [81] Borgstrom, E., et al. Phasing of single DNA molecules by massively parallel barcoding. Nat. Commun., 6, 2015, 8173.
82. [82] Bentley, D.R., et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456 (2008), 53–59.
83. [83] Adessi, C., et al. Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms. Nucleic Acids Res., 28, 2000, E87.
84. [84] Fedurco, M., Romieu, A., Williams, S., Lawrence, I., Turcatti, G., BTA, a novel reagent for DNA attachment on glass and efficient generation of solid-phase amplified DNA colonies. Nucleic Acids Res., 34, 2006, e22.
85. [85] Cao, M.D., et al. Inferring short tandem repeat variation from paired-end short reads. Nucleic Acids Res., 42, 2014, e16.
86. [86] Zhang, J., Kobert, K., Flouri, T., Stamatakis, A., PEAR: a fast and accurate Illumina paired-end reAd mergeR. Bioinformatics 30 (2014), 614–620.
87. [87] Bashir, A., Volik, S., Collins, C., Bafna, V., Raphael, B.J., Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. PLoS Comput. Biol., 4, 2008, e1000051.
88. [88] Lin, S., Wu, Y., Gunderson, K., Moon, J., Patterned flow-cells useful for nucleic acid analysis. US Patent App. 13/492,661 http://www.google.com/patents/US20120316086, 2012.
89. [89] Shen, M.J.R., et al. Kinetic exclusion amplification of nucleic acid libraries. https://www.google.com/patents/US8895249, 2014.
90. [90] Sheridan, C., Milestone approval lifts Illuminas NGS from research into clinic. Nat. Biotechnol. 32 (2014), 111–112.
91. [91] Grosu, D.S., et al. Clinical investigational studies for validation of a next-generation sequencing in vitro diagnostic device for cystic fibrosis testing. Expert. Rev. Mol. Diagn. 14 (2014), 605–622.
92. [92] Baker, M.W., et al. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. Genet. Med., 2015, 10.1038/gim.2014.209.
93. [93] Merriman, B., Rothberg, J.M., Progress in Ion Torrent semiconductor chip based sequencing. Electrophoresis 33 (2012), 3397–3417.
94. [94] Stevenson, M., Thermo raises a new platform for the clinical NGS market. http://www.clpmag.com/2014/09/thermo-raises-new-platform-clinical-ngs-market, 2014.
95. [95] Au, K.F., Sebastiano, V., The transcriptome of human pluripotent stem cells. Curr. Opin. Genet. Dev. 28 (2014), 71–77.
96. [96] Coupland, P., Chandra, T., Quail, M., Reik, W., Swerdlow, H., Direct sequencing of small genomes on the pacific biosciences RS without library preparation. Biotechniques 53 (2012), 365–372.
97. [97] Cavelier, L., et al. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing. BMC Cancer, 15, 2015, 45.
98. [98] Loomis, E.W., et al. Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. Genome Res. 23 (2013), 121–128.
99. [99] Minoche, A.E., et al. Exploiting single-molecule transcript sequencing for eukaryotic gene prediction. Genome Biol. 16 (2015), 1–13.
100. [100] Eid, J., et al. Real-time DNA sequencing from single polymerase molecules. Science 323 (2009), 133–138.
101. [101] Howorka, S., Cheley, S., Bayley, H., Sequence-specific detection of individual DNA strands using engineered nanopores. Nat. Biotechnol. 19 (2001), 636–639.
102. [102] Clarke, J., et al. Continuous base identification for single-molecule nanopore DNA sequencing. Nat. Nanotechnol. 4 (2009), 265–270.
103. [103] Kasianowicz, J.J., Brandin, E., Branton, D., Deamer, D.W., Characterization of individual polynucleotide molecules using a membrane channel. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 13770–13773.
104. [104] Stoddart, D., Maglia, G., Mikhailova, E., Heron, A.J., Bayley, H., Multiple base-recognition sites in a biological nanopore: two heads are better than one. Angew. Chem. Int. Ed. 49 (2010), 556–559.
105. [105] Laszlo, A.H., et al. Decoding long nanopore sequencing reads of natural DNA. Nat. Biotechnol. 32 (2014), 829–834.
106. [106] Butler, T.Z., Pavlenok, M., Derrington, I.M., Niederweis, M., Gundlach, J.H., Single-molecule DNA detection with an engineered MspA protein nanopore. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 20647–20652.
107. [107] Timp, W., Comer, J., Aksimentiev, A., DNA base-calling from a nanopore using a viterbi algorithm. Biophys. J. 102 (2012), L37–L39.
108. [108] Kilianski, A., et al. Bacterial and viral identification and differentiation by amplicon sequencing on the MinION nanopore sequencer. Gigascience, 4, 2015, 12.
109. [109] Koren, S., Phillippy, A.M., One chromosome, one contig: complete microbial genomes from long-read sequencing and assembly. Curr. Opin. Microbiol. 23 (2015), 110–120.
110. [110] Madoui, M.-A., et al. Genome assembly using nanopore-guided long and error-free DNA reads. BMC Genomics, 16, 2015, 327.
111. [111] Karlsson, E., LŠrkeryd, A., Sjšdin, A., Forsman, M., Stenberg, P., Scaffolding of a bacterial genome using MinION nanopore sequencing. Sci. Rep., 5, 2015, 11996.
112. [112] Kumar, S., et al. PEG-labeled nucleotides and nanopore detection for single molecule DNA sequencing by synthesis. Sci. Rep. 2 (2012), 1–8.
113. [113] Frampton, G.M., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31 (2013), 1023–1031.
114. [114] Lanman, R.B., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One, 10, 2015, e0140712.
115. [115] Lovett, M., Kere, J., Hinton, L.M., Direct selection: a method for the isolation of cDNAs encoded by large genomic regions. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 9628–9632.
116. [116] Bashiardes, S., et al. Direct genomic selection. Nat. Methods 2 (2005), 63–69.
117. [117] Gnirke, A., et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27 (2009), 182–189.
118. [118] Adey, A., et al. In vitro, long-range sequence information for de novo genome assembly via transposase contiguity. Genome Res. 24 (2014), 2041–2049.
119. [119] Picelli, S., et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9 (2014), 171–181.
120. [120] Chilamakuri, C.S.R., et al. Performance comparison of four exome capture systems for deep sequencing. BMC Bioinf., 15, 2014, 449.
121. [121] Pel, J., et al. Nonlinear electrophoretic response yields a unique parameter for separation of biomolecules. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 14796–14801.
122. [122] Marziali, A., Pel, J., Bizzotto, D., Whitehead, L.A., Novel electrophoresis mechanism based on synchronous alternating drag perturbation. Electrophoresis 26 (2005), 82–90.
123. [123] Kidess, E., et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 6 (2015), 2549–2561.
124. [124] Hovelson, D.H., et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 17 (2015), 385–399.
125. [125] Belardinilli, F., et al. Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. Clin. Biochem. 48 (2015), 71–73.
126. [126] Life Technologies, Ion AmpliSeq TM Designer provides full flexibility to sequence genes of your choice. Appl. Note, 2013.
127. [127] Ion Torrent. Oncomine Comprehensive Assay. (2014). at http://www.thermofisher.com/us/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-cancer-research-panel-workflow.html Ion Torrent. Oncomine Focus Assay. (2014). at http://www.thermofisher.com/us/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-focus-assay.html.
128. [128] Illumina, TruSeq Custom Amplicon Library Preparation Guide. 15027983 R. 2013.
129. [129] Agilent Technologies, HaloPlex Target Enrichment System for Illumina Sequencing. 2015.
130. [130] Miya, F., et al. A combination of targeted enrichment methodologies for whole-exome sequencing reveals novel pathogenic mutations. Sci. Rep., 5, 2015, 9331.
131. [131] Berglund, E.C., et al. Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment. BMC Genomics, 14, 2013, 856.
132. [132] Moens, L.N.J., et al. HaloPlex targeted resequencing for mutation detection in clinical formalin-fixed, paraffin-embedded tumor samples. J. Mol. Diagn. 17 (2015), 729–739.
133. [133] Cameron, D.E., Bashor, C.J., Collins, J.J., A brief history of synthetic biology. Nat. Rev. Microbiol. 12:5 (2014), 381–390.
134. [134] Gibson, D.G., et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 329:5987 (2010), 52–56.
135. [135] Borovkov, A.Y., et al. High-quality gene assembly directly from unpurified mixtures of microarray-synthesized oligonucleotides. Nucleic Acids Res., 38(19), 2010, e180-e180.
136. [136] Kosuri, S., Church, G.M., Large-scale de novo DNA synthesis: technologies and applications. Nat. Methods 11:5 (2014), 499–507 (Chicago).
137. [137] Mali, P., et al. RNA-guided human genome engineering via Cas9. Science 339:6121 (2013), 823–826.
138. [138] Kotula, J.W., Kerns, S.J., Shaket, L.A., Siraj, L., Collins, J.J., Way, J.C., Silver, P.A., Programmable bacteria detect and record an environmental signal in the mammalian gut. Proc. Natl. Acad. Sci. 111:13 (2014), 4838–4843.
139. [139] Pardee, K., Green, A.A., Ferrante, T., Cameron, D.E., DaleyKeyser, A., Yin, P., Collins, J.J., Paper-based synthetic gene networks. Cell 159:4 (2014), 940–954.
140. [140] Collins, Francis S., Varmus, Harold, A new initiative on precision medicine. N. Engl. J. Med. 372 (2015), 793–795.
141. [141] Burd, Eileen M., Validation of laboratory-developed molecular assays for infectious diseases. Clin. Microbiol. Rev. 23 (2010), 550–576.
142. [142] Fan, H.C., Gu, W., Wang, J., Blumenfeld, Y.J., El-Sayed, Y.Y., Quake, S.R., Non-invasive prenatal measurement of the fetal genome. Nature 487 (2012), 320–324.
143. [143] Wright, C.F., Burton, H., The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum. Reprod. Update 15 (2009), 139–151.
144. [144] Blaser, M.J., Harnessing the power of the human microbiome. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 6125–6126.
145. [145] Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R., Gordon, J.I., The human microbiome project. Nature 449 (2007), 804–810.
146. [146] http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm123682.htm.
147. [147] Bonington, A., et al. Use of Roche AMPLICOR mycobacterium tuberculosis PCR in early diagnosis of tuberculous meningitis. J. Clin. Microbiol. 36 (1998), 1251–1254.
148. [148] Abou Tayoun, A.N., et al. A comprehensive assay for CFTR mutational analysis using next-generation sequencing. Clin. Chem. 59 (2013), 1481–1488.
149. [149] https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html-redirect=/clia/.
150. [150] Cronin, M., et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53 (2007), 1084–1091.
151. [151] AdvaMedDx, Introduction to Molecular Diagnostics. 2013, 1–19.
152. [152] Kwong, A., et al. The importance of analysis of long range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genet. 208 (2015), 448–454.
153. [153] Lange, V., et al. Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing. BMC Genomics, 15, 2014, 63.
154. [154] Tewhey, R., et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat. Biotechnol. 27 (2009), 1025–1031.
155. [155] Ocwieja, K.E., et al. Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. Nucleic Acids Res 40 (2012), 10345–10355.
156. [156] Tung, N., et al. Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next-generation sequencing with a 25-gene panel. Cancer 121 (2015), 25–33.
157. [157] RainDance, RainDance ThunderBolts TM Cancer Panel. 2015.